Document Type : Review Paper
Authors
1 Chemistry Department, College of Science, Mustansiriyah University, Baghdad, Iraq.
2 Biology Department, College of Science, University of Anbar, Anbar, Iraq.
3 Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.
Abstract
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emergence in late 2019 marked the introduction of a highly spread viral pathogen threatening human population globally. The new virus is closely related genetically and clinically to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). There are no specific antiviral drugs approved against human coronavirus infection and all treatments are supportive. The genome of coronavirus contains several open reading frames (ORFs) that encode both non-structural proteins (nsp) and structural proteins. Most of the encoded proteins have been reported as multifunctional proteins and plays a specific role in coronavirus (CoV) replication and assembly. This review focuses on the potential vaccine and antiviral targets for coronavirus, including different proteins and genes. Understanding the current targets and discovering new possible therapeutic targets will help toward developing effective vaccines and antiviral drug against current SARS-CoV-2 outbreak and possible future outbreak.
Keywords
Main Subjects
1] Woo PC, Lau SK, Lam CS, Lai KK, Huang Y, Lee P, et al. Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus. J Virol. 2009;83(2):908–17.
[2] De Groot,RJ, AMQ K, Adams MJ, Cartens E, Lefkowitz EJ. Virus taxonomy, the 9th report of the international committe on taxonomy of viruses. Vol. 9. Academic Press,San Diego,CA; 2012. 806-828 p.
[3] Nauwynck H, Snijder EJ, Faaberg, Balasuriya U, Brinton M, Gorbalenya AE, et al. Family Arteriviridae. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (eds)Virus Taxonomy:IXth report of the International Committe of Taxonomy. Vol. 9. 2012. 796-805 p.
[4] Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008.
[5] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;
[6] Weiss SR. Forty years with coronaviruses. J Exp Med (Internet). 2020 May 4 (cited 2021 Jun 23);217(5). Available from: https://rupress.org/jem/article/217/5/e20200537/151597/Forty-years-with-coronavirusesForty-years-with
[7] Al-Jameel W, Al-Mahmood SS. Similarities and differences of COVID-19 and avian infectious bronchitis from molecular pathologist and poultry specialist view point. Iraqi J Vet Sci. 2020;34(2):223–31.
[8] Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol. 2019 Sep 8;73(1):529–57.
[9] Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–76.
[10] Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet. 2003;361(9366):1319–25.
[11] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.
[12] Perlman S. Another decade, another coronavirus. Mass Medical Soc; 2020.
[13] Gorbalenya AE, Baker SC, Baric RS, Groot RJ de, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv. 2020 Feb 11;2020.02.07.937862.
[14] Corman VM, Muth D, Niemeyer D, Drosten C. Chapter Eight - Hosts and Sources of Endemic Human Coronaviruses. In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. Advances in Virus Research (Internet). Academic Press; 2018. p. 163–88. Available from: https://www.sciencedirect.com/science/article/pii/S0065352718300010
[15] Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng B-H, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccines Immunother. 2016 Sep 1;12(9):2351–6.
[16] Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, et al. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol. 2017;91(1):e01651–16.
[17] Zhang N, Tang J, Lu L, Jiang S, Du L. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015 Apr 16;202:151–9.
[18] Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35(16):2069–75.
[19] De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523.
[20] Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev. 2006;19(4):614–36.
[21] Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013 Dec;11(12):836–48.
[22] Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar 1;59(3):252–6.
[23] Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report. Antivir Ther. 2015;21(5):455–9.
[24] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14.
[25] Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology. 2003;8(s1):S25–S30.
[26] Wu C-Y, Jan J-T, Ma S-H, Kuo C-J, Juan H-F, Cheng Y-SE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012–7.
[27] Falzarano D, De Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3:1686.
[28] Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–3.
[29] Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis. 2004;189(7):1164–7.
[30] Rossignol J-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016 Jun;9(3):227–30.
[31] Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016 Apr 22;291(17):9218–32.
[32] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4.
[33] Mousa YJ, Mahmood MB, Isihaq FA, Mohammed AA. Are promising mechanisms of hydroxychloroquine abolish COVID-19 activity? A review study. Iraqi J Vet Sci. 2020;34(2):345–9.
[34] Verma K, Kumar I. CHLOROQUINE AND HYDROXYCHLOROQUINE: A MAJOR BREAKTHROUGH FOR COVID-19. Int J Pharm Pharm Sci. 2020 Aug 18;1–5.
[35] Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–93.
[36] Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, et al. Identification of a Broad-Spectrum Antiviral Small Molecule against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay. J Virol. 2014 Apr 15;88(8):4353–65.
[37] Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088–99.
[38] Wadhwa P. MOLECULAR DOCKING STUDY OF NOVEL COVID-19 PROTEASE WITH CURRENT CLINICAL MANAGEMENT AGENTS. Asian J Pharm Clin Res. 2020 Jul 1;37–9.
[39] Chen Y, Lear T, Evankovich J, Larsen M, Lin B, Alfaras I, et al. A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry. 2020;
[40] Kainulainen MH, Bergeron E, Chatterjee P, Chapman AP, Lee J, Chida A, et al. High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay. Sci Rep. 2021;11(1):1–9.
[41] Li Q, Kang C. Progress in developing inhibitors of SARS-CoV-2 3C-like protease. Microorganisms. 2020;8(8):1250.
[42] Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004;78(24):13600–12.
[43] Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281(18):4085–96.
[44] Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, et al. SARS-CoV ORF1b-encoded nonstructural proteins 12–16: replicative enzymes as antiviral targets. Antiviral Res. 2014;101:122–30.
[45] Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82(5):2515–27.
[46] Báez-Santos YM, John SES, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38.
[47] Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res. 2013;100(1):286–95.
[48] Kuo C-J, Liang P-H. Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus. ChemBioEng Rev. 2015;2(2):118–32.
[49] Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem. 2016;59(14):6595–628.
[50] Zhao Q, Weber E, Yang H. Recent developments on coronavirus main protease/3C like protease inhibitors. Recent Patents Anti-Infect Drug Disc. 2013;8(2):150–6.
[51] Kumar V, Shin JS, Shie J-J, Ku KB, Kim C, Go YY, et al. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017;141:101–6.
[52] Fischer A, Sellner M, Neranjan S, Lill MA, Smieško M. Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds. 2020;
[53] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565–74.
[54] Chan JF-W, Yao Y, Yeung M-L, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–13.
[55] Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Case report Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21:455–9.
[56] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–99.
[57] Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun. 2019;10(1):1–9.
[58] Lee J-M, Cho J-B, Ahn H-C, Jung W, Jeong Y-J. A novel chemical compound for inhibition of SARS coronavirus helicase. J Microbiol Biotechnol. 2017;27:2070–3.
[59] Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis (Internet). 2020 Mar 5; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129391/
[60] Zhu S, Guo X, Geary K, Zhang D. Emerging Therapeutic Strategies for COVID-19 patients. Discoveries. 2020;8(1).
[61] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun 1;178:104787.
[62] Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects. PLoS Med (Internet). 2006 Sep;3(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/
[63] Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis. 2003;37(Supplement_4):S315–S322.
[64] Cobb AJ, Dell’Isola A, Abdulsattar BO, McLachlan MM, Neuman BW, Müller C, et al. Synthesis and antiviral activity of novel spirocyclic nucleosides. New J Chem. 2018;42(22):18363–80.
[65] Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother. 2014;58(8):4894–8.
[66] Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;1–13.
[67] Züst R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, et al. Ribose 2′- O -methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol. 2011 Feb;12(2):137–43.
[68] Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LLM, et al. Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage. J Mol Biol. 2003 Aug 29;331(5):991–1004.
[69] Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, Canard B, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. 2010;6(4).
[70] Ferron F, Decroly E, Selisko B, Canard B. The viral RNA capping machinery as a target for antiviral drugs. Antiviral Res. 2012 Oct 1;96(1):21–31.
[71] He ML, Zheng BJ, Chen Y, Wong KL, Huang JD, Lin MC, et al. Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication. Hong Kong Med J Xianggang Yi Xue Za Zhi (Internet). 2009; Available from: https://hub.hku.hk/handle/10722/147608
[72] Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, Canard B, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. 2010;6(4):e1000863.
[73] Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, et al. Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2′-O-methyltransferase activity of nsp10/nsp16 complex. Virus Res. 2012 Aug 1;167(2):322–8.
[74] Cheng K-W, Cheng S-C, Chen W-Y, Lin M-H, Chuang S-J, Cheng I-H, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9–16.
[75] Wang Y, Sun Y, Wu A, Xu S, Pan R, Zeng C, et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J Virol. 2015;89(16):8416–27.
[76] Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.
[77] Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses. 2012;4(4):557–80.
[78] Thorp EB, Boscarino JA, Logan HL, Goletz JT, Gallagher TM. Palmitoylations on murine coronavirus spike proteins are essential for virion assembly and infectivity. J Virol. 2006;80(3):1280–9.
[79] Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279(5):3197–201.
[80] Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–61.
[81] Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining “host jump”of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23(8):468–78.
[82] Sainz B, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res. 2006;120(1):146–55.
[83] Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol. 2013;87(24):13134–40.
[84] Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012;22(1):2–17.
[85] Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci. 2015;112(28):8738–43.
[86] Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014;88(12):7045–53.
[87] Jiang L, Wang N, Zuo T, Shi X, Poon K-MV, Wu Y, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6(234):234ra59–234ra59.
[88] Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101(8):2536–41.
[89] Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88(14):7796–805.
[90] Cavanagh D. Coronaviridae: a review of coronaviruses and toroviruses. In: Coronaviruses with Special Emphasis on First Insights Concerning SARS (Internet). Springer; 2005 (cited 2017 Feb 16). p. 1–54. Available from: http://link.springer.com/chapter/10.1007/3-7643-7339-3_1
[91] Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–36.
[92] Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10–8.
[93] Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, et al. One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 2017;91(2):e02040–16.
[94] Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020 Mar 28;105955.
[95] Yan Z-P, Yang M, Lai C-L. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals. 2021 May;14(5):406.
[96] Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. 2007;16(9):2065–71.
[97] Corse E, Machamer CE. Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. J Virol. 2000;74(9):4319–26.
[98] Liao Y, Yuan Q, Torres J, Tam JP, Liu DX. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology. 2006;349(2):264–75.
[99] Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292.
[100] Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J Virol. 2010 Nov;84(21):11418–28.
[101] Hogue BG, Machamer CE. Coronavirus structural proteins and virus assembly. Nidoviruses ASM Press Wash DC. 2008;179–200.
[102] Siu K-L, Kok K-H, Ng M-HJ, Poon VK, Yuen K-Y, Zheng B-J, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3· TANK· TBK1/IKKϵ complex. J Biol Chem. 2009;284(24):16202–9.
[103] AAkerström S, Mirazimi A, Tan Y-J. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antiviral Res. 2007;73(3):219–27.
[104] Almazán F, Galán C, Enjuanes L. The nucleoprotein is required for efficient coronavirus genome replication. J Virol. 2004;78(22):12683–8.
[105] Tylor S, Andonov A, Cutts T, Cao J, Grudesky E, Van Domselaar G, et al. The SR-rich motif in SARS-CoV nucleocapsid protein is important for virus replication. Can J Microbiol. 2009;55(3):254–60.
[106] Chang C, Lo S-C, Wang Y-S, Hou M-H. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today. 2016;21(4):562–72.
[107] Ma Y, Tong X, Xu X, Li X, Lou Z, Rao Z. Structures of the N-and C-terminal domains of MHV-A59 nucleocapsid protein corroborate a conserved RNA-protein binding mechanism in coronavirus. Protein Cell. 2010;1(7):688–97.
[108] Chang C, Sue S-C, Yu T, Hsieh C-M, Tsai C-K, Chiang Y-C, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci. 2006;13(1):59–72.
[109] Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J Virol. 2009;83(14):7221–34.
[110] Che X-Y, Hao W, Wang Y, Di B, Yin K, Xu Y-C, et al. Nucleocapsid protein as early diagnostic marker for SARS. Emerg Infect Dis. 2004;10(11):1947.
[111] Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, et al. Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein. medRxiv. 2020;
[112] Xiong S, Wang Y-F, Zhang M-Y, Liu X-J, Zhang C-H, Liu S-S, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett. 2004;95(2):139–43.
[113] Leung DTM, Hang TFC, Hung MC, Chan PKS, Cheung JLK, Niu H, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis. 2004;190(2):379–86.
[114] Thiel V, Herold J, Schelle B, Siddell SG. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol. 2001 Jun 1;82(6):1273–81.
[115] Zúñiga S, Sola I, Moreno JL, Sabella P, Plana-Durán J, Enjuanes L. Coronavirus nucleocapsid protein is an RNA chaperone. Virology. 2007;357(2):215–27.
[116] Hurst KR, Kuo L, Koetzner CA, Ye R, Hsue B, Masters PS. A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein. J Virol. 2005;79(21):13285–97.
[117] Lin S-Y, Liu C-L, Chang Y-M, Zhao J, Perlman S, Hou M-H. Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target. J Med Chem. 2014;57(6):2247–57.
[118] Luo H, Chen J, Chen K, Shen X, Jiang H. Carboxyl terminus of severe acute respiratory syndrome coronavirus nucleocapsid protein: self-association analysis and nucleic acid binding characterization. Biochemistry (Mosc). 2006;45(39):11827–35.
[119] Zhao P, Cao J, Zhao L-J, Qin Z-L, Ke J-S, Pan W, et al. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005;331(1):128–35.
[120] Zhu M-S, Pan Y, Chen H-Q, Shen Y, Wang X-C, Sun Y-J, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett. 2004;92(3):237–43.
[121] Takeda M, Chang C, Ikeya T, Güntert P, Chang Y, Hsu Y, et al. Solution structure of the c-terminal dimerization domain of SARS coronavirus nucleocapsid protein solved by the SAIL-NMR method. J Mol Biol. 2008;380(4):608–22.
[122] Tang T-K, Wu MP-J, Chen S-T, Hou M-H, Hong M-H, Pan F-M, et al. Biochemical and immunological studies of nucleocapsid proteins of severe acute respiratory syndrome and 229E human coronaviruses. Proteomics. 2005;5(4):925–37.
[123] Di B, Hao W, Gao Y, Wang M, Qiu L, Wen K, et al. Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. Clin Diagn Lab Immunol. 2005;12(1):135–40.
[124] Surjit M, Lal SK. The SARS-CoV nucleocapsid protein: a protein with multifarious activities. Infect Genet Evol. 2008;8(4):397–405.
[125] Al-Aalim AM, Hamad MA, AL-ledani Ali A. Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects. Iraqi J Vet Sci. 2020;34(2):287–93.
)
